Table 2.
Summary of Events and Targeted Toxicities by Treatment Group
| Event Type | No. of Events | P | ||
|---|---|---|---|---|
| Doxorubicin Alone (n = 264) | Doxorubicin + Dexrazoxane (n = 273) | Total (N = 537) | ||
| Induction failure | 13 | 17 | 30 | |
| Relapse | 43 | 38 | 81 | |
| Marrow ± other | 16 | 18 | 34 | |
| CNS ± other | 18 | 13 | 31 | |
| Other | 9 | 7 | 16 | |
| Toxic death | 3 | 6 | 9 | |
| Induction | 1 | 2 | 3 | |
| Remission | 2 | 4 | 6 | |
| Secondary malignant neoplasm | 3: n = 1 each myeloid sarcoma, AMML, DLBL | 8: n = 2 AML, n = 2 astrocytoma, n = 2 GBM, n = 1 medulloblastoma papillary carcinoma (thyroid) | 11 | |
| Total events | 62 | 69 | 131 | |
| Grade 3 or 4 toxicities | ||||
| Infection | 168 | 173 | .64 | |
| Hematologic effects | 237 | 243 | .26 | |
| Mucositis | 52 | 33 | .02 | |
| CNS effects | 23 | 28 | .46 | |
Abbreviations: AML, acute myeloblastic leukemia; AMML, acute myelomonocytic leukemia; DLBL, diffuse large B-cell lymphoma; GBM, glioblastoma multiforme.